Research Links Prenatal Cannabis Exposure to Schizophrenia Risk

Schizophrenia, a severe mental health disorder marked by psychosis, affects approximately 1% of the Canadian population. This condition poses significant health challenges, including a reduced life expectancy. Recent research has shed light on how prenatal factors, particularly cannabis exposure, may increase the risk of developing schizophrenia later in life.

Various elements contribute to the risk of schizophrenia, including prenatal environmental conditions such as malnutrition and drug exposure, family history, childhood trauma, and urban upbringing. Despite these known risk factors, there are currently no reliable biomarkers for early identification of the disorder. Early diagnosis is crucial as it can lead to improved treatment outcomes. Researchers are now investigating the placenta as a potential source of early indicators for schizophrenia risk.

The Placenta-Brain Connection

The concept of the placenta-brain axis suggests that the placenta records the conditions experienced during pregnancy, reflecting both healthy and unhealthy environments for the developing fetus. Studies have demonstrated that pregnancies resulting in low birth weight babies show changes in certain genetic markers within the placenta. These markers correlate with a heightened risk of schizophrenia and other adverse behavioral outcomes, including autism and cognitive impairments.

The legalization of cannabis in Canada in 2018 has led to a concerning rise in prenatal cannabis use, which has been reported at rates as high as 24% among pregnant teenagers aged 13 to 19 years. While it is established that cannabis use during pregnancy is associated with low birth weight, its impact on placental biomarkers related to schizophrenia remains unclear.

To address this gap, researchers at Western University conducted a study published in the journal Biology of Reproduction, investigating the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, on placental markers associated with schizophrenia.

Research Findings on THC Exposure

Led by Daniel Hardy, a professor in the Department of Obstetrics and Gynaecology at Western University, the research team, including master’s student Andrea Kocsis and several collaborators, employed a preclinical rodent model. Pregnant rodents were administered edible THC mixed with Nutella. The findings revealed that both male and female offspring exposed to THC exhibited reduced prepulse inhibition early in life, a psychological test used in diagnosing schizophrenia in humans. This test evaluates the brain’s ability to filter out irrelevant stimuli, which is crucial for normal cognitive function.

Additionally, the placentae of these THC-exposed offspring demonstrated increases in several human placental markers linked to schizophrenia risk. The research team also investigated whether similar changes occurred in human cell cultures, finding that isolated human placental cells treated with THC for 24 hours exhibited comparable increases in schizophrenia-related genes.

These findings carry significant clinical implications. While it is always advisable to cease cannabis use during pregnancy, many individuals find this challenging due to social or habitual dependencies. Consequently, some children may be inadvertently exposed to cannabis in utero. Identifying cannabis-specific placental markers associated with schizophrenia risk could pave the way for early interventions, potentially mitigating negative behavioral outcomes through psychological or dietary strategies. Since schizophrenia typically manifests between the ages of 16 and 30, early identification at birth could be invaluable.

Further research is essential to determine whether other components of cannabis, like cannabidiol (CBD), also influence neurodevelopment or modify placental markers. It is equally important to explore how parental health and lifestyle choices, such as cannabinoid consumption before conception, may impact placental health and increase schizophrenia risk.

In light of these findings, the research provides crucial evidence for clinicians and regulatory bodies, including Health Canada, as they navigate policies regarding cannabis use during pregnancy. The implications of this research underscore the need for continued investigation into the intersection of prenatal exposures and long-term mental health outcomes.